GoResp Digihaler
Budesonide / Formoterol Fumarate Dihydrate – Digital Inhalation Powder
Quick Facts about GoResp Digihaler
Key Takeaways about GoResp Digihaler
- Dual-action inhaler: Combines budesonide (anti-inflammatory) and formoterol (bronchodilator) for comprehensive asthma and COPD management
- Built-in digital sensor: Automatically records inhaler use and syncs with a companion app to help track medication adherence
- Not a rescue inhaler alone: Primarily for regular maintenance treatment; always carry a separate short-acting reliever unless your doctor prescribes a MART regimen
- Rinse after every use: Always rinse your mouth with water after inhalation to prevent oral thrush (candidiasis) and hoarseness
- Avoid abrupt discontinuation: Never stop using GoResp Digihaler suddenly without medical advice, as this can trigger a severe asthma or COPD exacerbation
What Is GoResp Digihaler and What Is It Used For?
GoResp Digihaler is a combination inhalation powder containing budesonide (160 mcg) and formoterol fumarate dihydrate (4.5 mcg) per dose. It is used for the regular maintenance treatment of asthma in adults and adolescents aged 12 years and older, and for the symptomatic treatment of chronic obstructive pulmonary disease (COPD) in adults. The integrated digital sensor distinguishes it from conventional inhalers by tracking medication use.
GoResp Digihaler belongs to the class of combination inhaled corticosteroid and long-acting beta-2 agonist (ICS/LABA) inhalers. These medications are considered a cornerstone of therapy for persistent asthma and moderate-to-severe COPD, according to both the Global Initiative for Asthma (GINA) and the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines. The two active substances in GoResp Digihaler work together through complementary mechanisms to provide effective airway management.
Budesonide is an inhaled corticosteroid (ICS) that reduces inflammation in the airways. Airway inflammation is a central feature of both asthma and COPD, leading to swelling, excess mucus production, and narrowing of the bronchial passages. By suppressing this inflammatory response at the cellular level, budesonide helps reduce the frequency and severity of symptoms, prevent exacerbations, and protect against long-term airway remodeling. Budesonide has been used clinically for over 40 years and has an extensively documented safety and efficacy profile.
Formoterol fumarate dihydrate is a long-acting beta-2 adrenergic agonist (LABA) that works by relaxing the smooth muscle surrounding the airways, causing bronchodilation. Unlike short-acting bronchodilators such as salbutamol, formoterol provides a rapid onset of action (within 1–3 minutes) combined with a duration of effect lasting up to 12 hours. This makes it particularly effective for maintaining open airways throughout the day and night, reducing symptoms such as wheezing, shortness of breath, and chest tightness.
The Digihaler technology represents an advancement in inhaler design. The device contains a built-in electronic module with sensors that automatically detect and record each inhalation event, including peak inspiratory flow rate. This data can be transmitted wirelessly via Bluetooth to a companion smartphone application, allowing patients and their healthcare providers to monitor medication use patterns, assess adherence, and identify potential issues with inhaler technique. Studies have shown that poor inhaler adherence is one of the most significant modifiable risk factors for uncontrolled asthma, affecting up to 50–70% of patients prescribed maintenance inhalers.
Indications
GoResp Digihaler is indicated for the following conditions:
- Asthma: Regular maintenance treatment in adults and adolescents (12 years and older) where use of a combination ICS/LABA inhaler is appropriate. This includes patients not adequately controlled on inhaled corticosteroids alone, or patients already adequately controlled on both an ICS and a LABA.
- COPD: Symptomatic treatment of adults with severe COPD (FEV1 < 50% predicted) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with a long-acting bronchodilator.
International guidelines, including those from GINA and the FDA, emphasize that long-acting beta-2 agonists (LABAs) like formoterol should never be used as monotherapy for asthma. Using a LABA without an accompanying inhaled corticosteroid has been associated with an increased risk of serious asthma-related events. GoResp Digihaler addresses this by combining both components in a single inhaler, ensuring patients receive the anti-inflammatory corticosteroid with every dose of bronchodilator.
What Should You Know Before Taking GoResp Digihaler?
Before using GoResp Digihaler, inform your doctor if you have any infections, heart problems, diabetes, osteoporosis, or thyroid disorders. This medication should be used with caution during pregnancy and breastfeeding. Do not use GoResp Digihaler if you are allergic to budesonide, formoterol, or lactose (which is used as a carrier in the powder).
As with all prescription medications, there are important considerations before starting GoResp Digihaler. Your healthcare provider will assess your individual risk profile, current medications, and medical history to determine whether this inhaler is appropriate for you. Open communication with your doctor is essential to ensure safe and effective treatment.
Contraindications
GoResp Digihaler should not be used in the following situations:
- Hypersensitivity: Known allergy to budesonide, formoterol fumarate dihydrate, or any of the excipients, including lactose monohydrate (which contains small amounts of milk proteins)
- Age restriction: Not recommended for children under 12 years of age at the 160/4.5 mcg strength
Warnings and Precautions
Special caution is advised and your doctor may need to monitor you more closely if you have any of the following conditions:
- Active or quiescent tuberculosis of the lungs
- Fungal, viral, or bacterial respiratory infections – inhaled corticosteroids may mask symptoms of existing infections
- Cardiovascular disorders: including coronary artery disease, cardiac arrhythmias (particularly third-degree atrioventricular block), severe heart failure, hypertrophic obstructive cardiomyopathy, idiopathic subvalvular aortic stenosis, severe hypertension, or aneurysm
- QT prolongation: Formoterol may prolong the QTc interval; caution is needed if you have known QT prolongation or are taking QT-prolonging medications
- Diabetes mellitus: Inhaled corticosteroids may affect blood glucose control; more frequent monitoring may be required
- Untreated hypokalemia: Beta-2 agonists can reduce serum potassium levels, which may be clinically significant in patients already at risk
- Thyrotoxicosis (overactive thyroid)
- Pheochromocytoma (adrenal gland tumor)
- Osteoporosis: Long-term use of inhaled corticosteroids may reduce bone mineral density; this risk should be weighed against the benefits
- Adrenal suppression: Prolonged use of high-dose inhaled corticosteroids can suppress the hypothalamic-pituitary-adrenal (HPA) axis, particularly during periods of physiological stress
GoResp Digihaler is intended for regular maintenance treatment. It should not be used as the sole treatment for acute asthma attacks or acute bronchospasm. Patients should always have access to a separate short-acting bronchodilator (such as salbutamol) for acute relief, unless their prescriber has specifically initiated a maintenance and reliever therapy (MART) regimen. If you experience a sudden worsening of breathing, use your rescue inhaler and seek medical attention immediately.
Pregnancy and Breastfeeding
If you are pregnant, planning to become pregnant, or breastfeeding, discuss the use of GoResp Digihaler with your doctor before starting treatment. The decision to use this medication during pregnancy involves weighing the potential risks to the developing fetus against the well-established risks of poorly controlled asthma during pregnancy, which include pre-eclampsia, premature birth, and low birth weight.
Pregnancy: Extensive observational data on budesonide exposure during pregnancy (more than 10,000 exposed pregnancies documented) have not shown an increased risk of birth defects. GINA guidelines recommend that pregnant women with asthma should continue their controller medications, as the risks of uncontrolled asthma to both mother and baby outweigh the potential risks of inhaled corticosteroids. Data on formoterol use during pregnancy is more limited; animal studies at very high doses showed some reproductive toxicity, but the clinical relevance of these findings at inhaled therapeutic doses is uncertain.
Breastfeeding: Budesonide is excreted in human breast milk in small amounts. At therapeutic doses, the amount reaching the infant is expected to be negligible. There is limited information on formoterol in breast milk. The potential benefit to the mother should be weighed against any potential risk to the infant, but in most cases, continuation of treatment is considered acceptable.
How Does GoResp Digihaler Interact with Other Drugs?
GoResp Digihaler can interact with beta-blockers (which may reduce its bronchodilating effect), strong CYP3A4 inhibitors such as ketoconazole (which increase corticosteroid exposure), potassium-depleting drugs, and QT-prolonging medications. Always inform your doctor and pharmacist about all medications you are taking, including over-the-counter products and herbal supplements.
Drug interactions with GoResp Digihaler can affect the metabolism, efficacy, or safety of either the inhaled medication or the interacting drug. Both budesonide and formoterol have distinct pharmacological pathways that can be influenced by concurrent medications. The table below summarizes the most clinically important interactions.
Major Interactions
| Interacting Drug | Effect | Clinical Significance | Recommendation |
|---|---|---|---|
| Beta-blockers (e.g. propranolol, atenolol) | Block beta-2 receptors, reducing or abolishing the bronchodilating effect of formoterol | High – may cause severe bronchospasm | Avoid non-selective beta-blockers. If essential, use cardioselective beta-blockers with extreme caution |
| Strong CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, ritonavir) | Inhibit metabolism of budesonide, significantly increasing systemic corticosteroid exposure | High – risk of Cushing syndrome and adrenal suppression | Avoid prolonged co-administration. If unavoidable, monitor closely for corticosteroid side effects |
| QT-prolonging drugs (e.g. erythromycin, certain antihistamines, antipsychotics) | Combined QTc prolongation effect with formoterol may increase risk of cardiac arrhythmias | Moderate to high | Use with caution; ECG monitoring may be warranted |
Minor Interactions
| Interacting Drug | Effect | Recommendation |
|---|---|---|
| Potassium-depleting agents (loop diuretics, thiazides, corticosteroid tablets) | Formoterol can lower potassium; combined use increases risk of hypokalemia | Monitor serum potassium, especially in patients at risk of cardiac arrhythmias |
| Other sympathomimetic drugs (e.g. salmeterol, terbutaline) | Additive beta-2 agonist effects; increased risk of tachycardia, tremor, and hypokalemia | Avoid concurrent use unless specifically directed by prescriber |
| Phenytoin, phenobarbital, rifampicin (CYP3A4 inducers) | Increased metabolism of budesonide, potentially reducing its anti-inflammatory efficacy | Higher doses of budesonide may be needed; monitor asthma/COPD control |
| MAO inhibitors, tricyclic antidepressants | May potentiate the cardiovascular effects of formoterol (increased heart rate, blood pressure) | Use with caution; monitor cardiovascular parameters |
What Is the Correct Dosage of GoResp Digihaler?
The usual maintenance dose of GoResp Digihaler for adults with asthma is 1–2 inhalations twice daily (morning and evening). For COPD, the typical dose is 2 inhalations twice daily. The maximum recommended dose is 4 inhalations per day. Your doctor will prescribe the lowest dose that effectively controls your symptoms.
Dosing of GoResp Digihaler should be individualized based on the severity of your condition and your response to treatment. The goal is to achieve and maintain symptom control using the lowest effective dose. Once asthma or COPD symptoms are well-controlled for a sustained period, your doctor may consider stepping down the dose. Never change your dose without consulting your prescriber.
Adults
Asthma – Maintenance Therapy
Recommended dose: 1–2 inhalations twice daily (morning and evening)
Maximum dose: 4 inhalations per day (2 inhalations twice daily)
In some patients, a maintenance dose of 1 inhalation twice daily may be sufficient. Your doctor will titrate to the lowest effective dose after adequate control is achieved. If a once-daily dosing approach is considered, the preferred time is in the evening.
Asthma – Maintenance and Reliever Therapy (MART)
Maintenance dose: 1 inhalation twice daily (or 2 inhalations once daily)
As-needed relief: 1 additional inhalation as needed for symptoms
Maximum total dose: 6 inhalations in a single day
In the MART approach, GoResp Digihaler serves as both the daily maintenance inhaler and the reliever for breakthrough symptoms, replacing the need for a separate short-acting bronchodilator. If more than 6 inhalations are needed in a day, medical review is recommended.
COPD – Maintenance Therapy
Recommended dose: 2 inhalations twice daily
Maximum dose: 4 inhalations per day
The dose for COPD is fixed and should be maintained as prescribed. Patients should continue to carry a separate short-acting bronchodilator for acute episodes of breathlessness.
Adolescents (12 years and older)
Asthma
Recommended dose: 1–2 inhalations twice daily
Maximum dose: 4 inhalations per day
The dosing is the same as for adults. Growth should be regularly monitored in adolescents receiving prolonged treatment with inhaled corticosteroids. If growth retardation is observed, therapy should be reassessed.
Children (under 12 years)
GoResp Digihaler 160/4.5 mcg is not recommended for children under 12 years of age. Lower-strength budesonide/formoterol formulations may be available for younger children – consult your pediatrician or asthma specialist for guidance on appropriate treatment options.
Elderly
No dose adjustment is required in elderly patients. However, elderly patients may be more susceptible to certain side effects, including osteoporosis, cataracts, and glaucoma, with long-term inhaled corticosteroid use. Regular monitoring of bone density and intraocular pressure may be advisable for those on prolonged high-dose therapy. Elderly patients should also be assessed for their ability to use the dry powder inhaler correctly, as adequate inspiratory flow is required for effective drug delivery.
Missed Dose
If you forget to take a dose, take it as soon as you remember. However, if it is nearly time for your next dose, simply skip the missed dose and return to your regular schedule. Do not take a double dose to make up for the one you missed. The digital sensor in the Digihaler can help you keep track of whether you have taken your scheduled doses.
Overdose
An overdose of formoterol may cause tremor, headache, palpitations, tachycardia (rapid heartbeat), nausea, and potentially hypokalemia (low potassium) or hyperglycemia (high blood sugar). The cardiac effects may require monitoring in a healthcare setting. Chronic overdosage with the budesonide component may lead to systemic corticosteroid effects such as adrenal suppression, although this is unlikely with the inhaled route alone.
If you suspect an overdose, contact your doctor, go to the nearest emergency department, or call your local poison control center immediately. Take the inhaler device with you so that the healthcare team can see what has been taken.
Correct inhaler technique is essential for GoResp Digihaler to work effectively. Open the mouthpiece cover fully, exhale gently away from the device, seal your lips around the mouthpiece, and inhale deeply and forcefully. Hold your breath for about 10 seconds, then exhale normally. Close the cover after use. If a second inhalation is prescribed, wait approximately 30 seconds before repeating. Always rinse your mouth with water after your final inhalation and spit it out – do not swallow the rinse water.
What Are the Side Effects of GoResp Digihaler?
The most common side effects of GoResp Digihaler include oral thrush (candidiasis of the mouth and throat), hoarseness, throat irritation, cough, and headache. Most side effects are mild and can be minimized by rinsing your mouth after each use and using the correct inhalation technique. Serious side effects are uncommon but can include paradoxical bronchospasm, severe allergic reactions, and adrenal suppression with long-term high-dose use.
Like all medicines, GoResp Digihaler can cause side effects, although not everybody gets them. The side effects listed below are grouped by how frequently they occur based on clinical trial data and post-marketing surveillance. Many of the common side effects are related to the corticosteroid component (budesonide) and can be minimized by good inhaler technique and mouth rinsing, while others relate to the beta-2 agonist component (formoterol) and its stimulatory effects on the cardiovascular system.
Very Common (affects more than 1 in 10 people)
- Oral candidiasis (thrush in the mouth and throat)
Common (affects 1 to 10 in 100 people)
- Headache
- Hoarseness (dysphonia)
- Throat irritation and cough after inhalation
- Tremor (especially in the hands)
- Palpitations (awareness of heartbeat)
- Nasopharyngitis (common cold symptoms)
- Sinusitis
- Muscle cramps
Uncommon (affects 1 to 10 in 1,000 people)
- Tachycardia (rapid heartbeat)
- Cardiac arrhythmias (irregular heartbeat)
- Nausea
- Dizziness
- Sleep disturbances and restlessness
- Bruising of the skin
- Hypokalemia (low potassium levels)
- Anxiety and agitation
Rare (affects fewer than 1 in 1,000 people)
- Paradoxical bronchospasm (sudden worsening of breathing after inhalation)
- Immediate or delayed hypersensitivity reactions (rash, urticaria, angioedema)
- Adrenal suppression with prolonged high-dose use
- Growth retardation in children and adolescents
- Glaucoma and cataracts with long-term use
- Decreased bone mineral density
- Behavioral changes: depression, hyperactivity, irritability (especially in children)
- Anaphylactic reaction
- Sudden worsening of breathing immediately after inhalation (paradoxical bronchospasm)
- Swelling of the face, lips, tongue, or throat (angioedema)
- Severe skin rash or hives
- Chest pain, very rapid or irregular heartbeat
- Signs of a severe allergic reaction such as difficulty breathing, dizziness, or collapse
If you experience any side effects that are bothersome, persistent, or concerning, consult your doctor or pharmacist. You can also report side effects directly to your national medicines regulatory authority to help provide further information on the safety of this medicine.
How Should You Store GoResp Digihaler?
Store GoResp Digihaler at room temperature below 25°C (77°F), in its original packaging to protect from moisture. Keep the mouthpiece cover closed when not in use. Do not use the inhaler after the expiry date or after the dose counter reaches zero. Keep out of reach of children.
Proper storage of GoResp Digihaler is essential to maintain the effectiveness and stability of the medication, as well as the functioning of the integrated digital sensor. Inhalation powders are sensitive to moisture, which can cause the powder to clump and affect dose delivery.
- Temperature: Store below 25°C (77°F). Do not refrigerate or freeze the inhaler.
- Moisture protection: Keep the mouthpiece cover closed at all times when not in use. Store the inhaler in a dry place, away from humid environments such as bathrooms.
- Original packaging: Store in the original foil pouch until ready for first use. Once the foil pouch is opened, use the inhaler within the timeframe specified in the patient information leaflet (typically 6 months).
- Expiry date: Do not use GoResp Digihaler after the expiry date printed on the packaging and the device label. The dose counter on the device will count down from the total number of available doses.
- Dose counter: When the dose counter reaches zero, discard the inhaler even if it appears to contain powder, as accurate dosing can no longer be guaranteed.
- Children: Keep out of the sight and reach of children.
- Disposal: Do not throw away medications via household waste or wastewater. Ask your pharmacist how to dispose of medicines you no longer use, in accordance with local regulations.
The built-in electronic sensor is powered by an integrated battery that is designed to last for the lifetime of the inhaler. The battery is not user-replaceable. If the sensor stops functioning, the inhaler itself will continue to deliver medication normally – only the digital tracking feature is affected. Contact your pharmacist or healthcare provider if you notice the sensor is no longer syncing with the companion app.
What Does GoResp Digihaler Contain?
Each delivered dose of GoResp Digihaler contains 160 micrograms of budesonide and 4.5 micrograms of formoterol fumarate dihydrate as the active ingredients. The only excipient is lactose monohydrate, which serves as a carrier for the inhalation powder.
GoResp Digihaler has a simple formulation containing only the essential components needed for effective drug delivery via dry powder inhalation.
Active Ingredients
- Budesonide: 160 micrograms per delivered dose. Budesonide is a synthetic glucocorticoid with potent anti-inflammatory activity. It has high topical potency in the airways and undergoes extensive first-pass metabolism in the liver (approximately 90%), resulting in low systemic bioavailability when administered by inhalation.
- Formoterol fumarate dihydrate: 4.5 micrograms per delivered dose. Formoterol is a selective long-acting beta-2 adrenergic receptor agonist. It has a rapid onset of action (1–3 minutes) and a duration of effect of approximately 12 hours, making it suitable for twice-daily maintenance dosing.
Excipients
- Lactose monohydrate: This is a sugar derived from milk that serves as a carrier powder. It helps the fine drug particles flow through the inhaler and aids in deposition in the airways. Patients with severe lactose intolerance or a confirmed allergy to milk proteins should discuss this with their doctor, although the very small amounts of milk proteins present are unlikely to cause allergic reactions in most individuals.
The Digihaler Device
The inhaler device itself is a multi-dose dry powder inhaler made from medical-grade plastics. It contains an integrated electronic module comprising a flow sensor, accelerometer, Bluetooth transmitter, and a non-replaceable battery. The device is designed for single-patient use and should be discarded when the dose counter reaches zero or at the expiry date, whichever comes first. The electronic components are sealed within the device and do not come into contact with the medication.
Frequently Asked Questions about GoResp Digihaler
GoResp Digihaler is a combination inhaler containing budesonide (a corticosteroid) and formoterol (a long-acting bronchodilator) used for regular maintenance treatment of asthma in adults and adolescents aged 12 years and older where a combination inhaler is appropriate. It is also used for symptomatic treatment of COPD (chronic obstructive pulmonary disease) in adults. The built-in digital sensor tracks inhaler usage to help patients and healthcare providers monitor adherence.
GoResp Digihaler contains a built-in electronic sensor that automatically detects when the inhaler is used and records each inhalation event. This data can be synced wirelessly via Bluetooth to a companion smartphone app, allowing patients and their healthcare providers to track medication usage patterns, monitor adherence, and identify trends in inhaler use over time. The sensor also records peak inspiratory flow rate, which can help assess inhalation technique.
GoResp Digihaler is primarily a maintenance inhaler and should not be used as the sole treatment for acute asthma attacks. However, depending on your doctor's instructions, budesonide/formoterol inhalers may sometimes be prescribed in a maintenance and reliever therapy (MART) regimen, where the same inhaler is used for both daily maintenance and relief of symptoms. In MART, the maximum recommended dose is 6 inhalations per day. Always follow your doctor's specific instructions about how to use your inhaler and carry a separate rescue inhaler if advised to do so.
If you miss a dose of GoResp Digihaler, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a forgotten one. The digital sensor in the device can help you track whether you have taken your dose, and the companion app may send reminders.
Rinsing your mouth with water (and spitting it out) after each use helps prevent oral thrush (candidiasis) and hoarseness, which are common side effects of inhaled corticosteroids like budesonide. The corticosteroid can deposit in the mouth and throat during inhalation, creating an environment where the naturally present Candida fungus can overgrow. Rinsing removes these deposits and significantly reduces the risk of these side effects. Remember to spit out the water rather than swallowing it.
GoResp Digihaler 160/4.5 mcg is approved for adolescents aged 12 years and older for the treatment of asthma. It is not recommended for children under 12 years of age at this strength. Lower-strength budesonide/formoterol combinations may be available for younger children. Growth should be regularly monitored in adolescents receiving prolonged inhaled corticosteroid treatment. Consult a pediatrician or asthma specialist for the most appropriate treatment for children.
References
All information in this article is based on the following peer-reviewed sources, international guidelines, and regulatory documents:
- Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2024 Update. Available at: ginasthma.org
- Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for Prevention, Diagnosis and Management of COPD. 2024 Report. Available at: goldcopd.org
- European Medicines Agency (EMA). Summary of Product Characteristics: Budesonide/Formoterol combination inhalers. Available at: ema.europa.eu
- British National Formulary (BNF). Budesonide with formoterol. National Institute for Health and Care Excellence. Available at: bnf.nice.org.uk
- Papi A, et al. Inhaled corticosteroids and long-acting beta2-agonists in asthma: a review of current evidence. The Lancet Respiratory Medicine. 2022;10(7):699-711.
- World Health Organization (WHO). WHO Model List of Essential Medicines. 23rd List, 2023. Budesonide and formoterol are listed as essential medicines for respiratory conditions.
- Kerstjens HAM, et al. Digital inhaler technology in asthma and COPD: advances in monitoring and management. European Respiratory Journal. 2023;62(4):2300612.
- BTS/SIGN. British Guideline on the Management of Asthma. 2024 Update. Available at: brit-thoracic.org.uk
- Suissa S, et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. New England Journal of Medicine. 2000;343(5):332-336.
- Murphy AC, et al. Adherence to inhaled medications in asthma: a systematic review and meta-analysis. Journal of Allergy and Clinical Immunology: In Practice. 2021;9(6):2438-2448.
Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, which includes licensed specialist physicians in pulmonology, clinical pharmacology, and respiratory medicine.
iMedic Medical Editorial Team – specialists in respiratory medicine and clinical pharmacology with documented academic background and clinical experience in the management of asthma and COPD.
iMedic Medical Review Board – independent panel of board-certified pulmonologists and pharmacologists who verify all clinical content against current international guidelines (GINA, GOLD, EMA, BNF).
All medical information follows the GRADE evidence framework. This article has no pharmaceutical company sponsorship or commercial funding. Last reviewed: .